1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 5, 1, 20, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 5 and 1 molecules, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionInfluenza A Virus, H5N1 Subtype Infections - Overview
- Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Products under Development by Companies, 2021
- Products under Development by Universities/Institutes, 2021
- Number of Products by Stage and Target, 2021
- Number of Products by Stage and Mechanism of Action, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abivax SA, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by AlphaVax Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by AusBio Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by CHO Pharma Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac NV, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by CytoAgents Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Declion Pharmaceuticals Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by FluGen Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Global BioLife Inc Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Greffex Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by NuGenerex Immuno-Oncology Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Pneumagen Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Replikins Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Revelation Biosciences Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Seqirus Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Tria Bioscience Corp, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vacthera BioTech GmbH, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, 2021
- Influenza A Virus, H5N1 Subtype Infections - Pipeline by Virion Biotherapeutics, 2021
- Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, 2021
- Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, 2021
List of Figures
- Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abivax SA
- Abzyme Therapeutics LLC
- Akshaya Bio Inc
- AlphaVax Inc
- Altimmune Inc
- Aphios Corp
- AusBio Ltd
- BiondVax Pharmaceuticals Ltd
- Chicago Biosolutions Inc
- CHO Pharma Inc
- Cocrystal Pharma Inc
- Curevac NV
- CytoAgents Inc
- Declion Pharmaceuticals Inc
- Emergent BioSolutions Inc
- FluGen Inc
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- Gamma Vaccines Pty Ltd
- Global BioLife Inc Ltd
- Greffex Inc
- Inovio Pharmaceuticals Inc
- Medicago Inc
- Medigen Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- NuGenerex Immuno-Oncology Inc
- PeptiDream Inc
- Pneumagen Ltd
- Replikins Ltd
- Revelation Biosciences Inc
- Seqirus Ltd
- Shionogi & Co Ltd
- TechnoVax Inc
- Tria Bioscience Corp
- Vacthera BioTech GmbH
- Vaxart Inc
- Vaxine Pty Ltd
- Virion Biotherapeutics
